You are here

Mutant YK-11 Capsules

29 October 2018

Mutant YK-11 Capsules pose a serious risk to your health and should not be taken.

Photo of Mutant YK-11 capsules front packagingPhoto of Mutant YK-11 capsules rear packagingPhoto of Mutant YK-11 capsules

The Therapeutic Goods Administration (TGA) has tested a product labelled Mutant YK-11 Capsules and found that:

  • The capsules contain the undeclared substance tadalafil.

Consumers are advised that tadalafil is a prescription-only substance in Australia.

The supply of Mutant YK-11 Capsules containing undisclosed tadalafil is illegal.

Mutant YK-11 Capsules have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation, and the place of manufacture is not approved by the TGA.

TGA investigations have shown that a number of people in Australia may have bought the product online.

Information for consumers

  • Stop taking Mutant YK-11 Capsules and take any remaining capsules to your local pharmacy for safe disposal.
  • If you have any concerns arising from your use of this product, consult your health care practitioner.

Action the TGA is taking

The TGA is working with the Australian Border Force (ABF) to help stop future shipments of Mutant YK-11 Capsules from entering Australia.

If these capsules are found at the border by the ABF they will be seized and destroyed.

The TGA is advising consumers to exercise extreme caution when purchasing medicines from unknown overseas Internet sites and has produced a short video on the risks associated with buying medicines and medical devices online. Products purchased over the Internet:

  • may contain undisclosed and potentially harmful ingredients
  • may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia.

Report counterfeit medicines and medical devices

If you are worried about counterfeit medicines or medical devices, and want to report an issue, you can report the matter to the TGA:

Phone: 1800 020 653

Online: Report a perceived breach of the Therapeutic Goods Act or questionable practices relating to therapeutic products

Email: